The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 5 rounds in the feed, most often in Biotech.
Venture capitalsvhealthinvestors.comRounds from 2018-08-10 to 2026-07-15
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series D Verified against 4 of 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $315M | 2026-07-15 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. |
Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. |
| $115M |
| 2025-11-17 |
| [ LEAD ] |
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2025-02-03 | [ LEAD ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $84M | 2018-08-10 | [ PART ] |